Article Text

Download PDFPDF
582 CA125 and platinum free interval as potential predictive biomarkers of PARP inhibitors’ effectiveness in platinum-sensitive recurrent ovarian cancer: a multicentric retrospective analysis
  1. Floriana Camarda1,
  2. Lucia Musacchio1,
  3. Veronica Agostinelli2,
  4. Valentina Tuninetti3,
  5. Sabrina Chiara Cecere4,
  6. Gabriella Ferrandina1,
  7. Giorgio Valabrega3,
  8. Vanda Salutari1,
  9. Claudia Andreetta5,
  10. Francesco Raspagliesi6,
  11. Carmine De Angelis7,
  12. Rossella Lauria7,
  13. Marianna Roccio8,
  14. Gennaro Cormio9,
  15. Giacomo Corrado1,
  16. Saverio Cinieri10,
  17. Sofia Scandolara11,
  18. Sandro Pignata12,
  19. Giovanni Scambia1 and
  20. Domenica Lorusso1
  1. 1Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  2. 2Università Politecnica delle Marche – AUO delle Marche, Ancona, Italy
  3. 3Department of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital, Torino, Italy
  4. 4Pascale National Cancer Institute Foundation (IRCCS), Napoli, Italy
  5. 5Department of Medical Oncology, ‘S. Maria della Misericordia’ University Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy
  6. 6Fondazione IRCCS Istituto Nazionale dei Tumori, Gynecological Oncology Unit, Milan, Italy
  7. 7Università Federico II, Napoli, Italy
  8. 8Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
  9. 9IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
  10. 10Presidio Ospedaliero Sant Antonio Perrino, Brindisi, Italy
  11. 11IFO – Istituto Nazionale Tumori Regina Elena, Rome, Italy
  12. 12Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy


Introduction/Background In platinum-sensitive recurrent ovarian cancer (PSROC) patients, PARP inhibitors (PARPis) represent the first choice for maintenance therapy (if PARPis naïve). Several real word data suggested that a normalized CA125 at baseline, as well as a longer prior platinum free interval (PFI) could be predictive of a better outcome patients in PARPis era.

Methodology This is a real-world multicenter retrospective analysis including high grade serous and endometrioid PSROC patients who received PARPis after complete or partial response to platinum-based chemotherapy at the time of first or second recurrence. The objective of this exploratory analysis was to describe the predictive role of CA125 and PFI on the effectiveness of PARPi as maintenance therapy in a relapsed setting, in terms of progression free survival (PFS) and overall survival (OS).

Results Clinical data from a dataset including 519 patients were analyzed, among them 36% were BRCA 1–2 mutated. Cut off for CA125 normal value was settled at <35 U/ml. A normal range of CA125 at baseline after platinum-based chemotherapy and before starting PARPis maintenance was associated with a better PFS (mPFS 17.2 vs 5.9 months) and OS (mOS 92.5 vs 20.9 months). Furthermore, patients with a longer prior PFI (>12 m) seemed to benefit more from PARPi therapy than partially platinum sensitive patients (PFI: 6–12 months) both in terms of PFS (17 vs 9.6 months) and OS (not reached vs 24.9). Controversially BRCA status didn’t impact PFS and OS.

Conclusion Considering the limitations related to retrospective study, our data supports a maximal benefit from PARPi-based therapy in a population with a normal CA 125 value at baseline and a longer prior PFI.

Disclosures The authors declare no disclosures.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.